Skip to main content

previous disabled Page of 2
and
  1. No Access

    Article

    International recommendations for screening and preventative practices for long-term survivors of transplantation and cellular therapy: a 2023 update

    As hematopoietic cell transplantation (HCT) and cellular therapy expand to new indications and international access improves, the volume of HCT performed annually continues to rise. Parallel improvements in HC...

    Seth J. Rotz, Neel S. Bhatt, Betty K. Hamilton in Bone Marrow Transplantation (2024)

  2. No Access

    Article

    The association of body composition and outcomes following autologous hematopoietic stem cell transplantation in patients with non-Hodgkin lymphoma

    Recently there has been a growing interest in evaluating body composition as a marker for prognosis in cancer patients. The association of body composition parameters and outcomes has not been deeply investiga...

    Gabriel F. P. Aleixo, Wei Wei, Po-Hao Chen, Namita S. Gandhi in Bone Marrow Transplantation (2023)

  3. Article

    Open Access

    Prophylactic Trimethoprim-Sulfamethoxazole for Allogeneic Hematopoietic Stem Cell Transplant Recipients During the Pre-engraftment Period

    Our institution has used trimethoprim-sulfamethoxazole (TMP-SMX) as the antibacterial agent of choice for infection prophylaxis during the pre-engraftment period in the allogeneic transplant (allo-HCT) populat...

    Kelly J. Gaffney, Theresa A. Urban, Mariana Lucena in Clinical Hematology International (2023)

  4. Article

    Open Access

    Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation

    Graft-versus-leukemia (GvL) reactions are responsible for the effectiveness of allogeneic hematopoietic cell transplantation as a treatment modality for myeloid neoplasia, whereby donor T- effector cells recog...

    Simona Pagliuca, Carmelo Gurnari, Colin Hercus in Nature Communications (2023)

  5. No Access

    Article

    Resource utilization in patients with large B-cell lymphoma receiving tisagenlecleucel and axicabtagene ciloleucel

    Agrima Mian, Wei Wei, Betty K. Hamilton, Allison M. Winter in Bone Marrow Transplantation (2023)

  6. No Access

    Article

    Pattern of somatic mutation changes after allogeneic hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes

    Sanghee Hong, Lisa Rybicki, Carmelo Gurnari, Simona Pagliuca in Bone Marrow Transplantation (2022)

  7. No Access

    Article

    Evaluation of pre-transplant risk assessments in allogeneic hematopoietic cell transplant

    Pranay S. Hegde, Lisa Rybicki, Sheila Serafino in Bone Marrow Transplantation (2022)

  8. No Access

    Article

    Community health status and long-term outcomes in 1-year survivors of autologous and allogeneic hematopoietic cell transplantation

    Julia H. Joo, Sanghee Hong, Lisa A. Rybicki in Bone Marrow Transplantation (2022)

  9. Chapter

    Introduction

    Cancer is a growing healthcare problem worldwide with significant public health and economic burden to both developed and develo** countries. According to the World Health Organization, cancer is the second ...

    Mahmoud Aljurf, Navneet S. Majhail, Mickey B. C. Koh in The Comprehensive Cancer Center (2022)

  10. No Access

    Article

    Day 100 risk assessment tool predicts overall survival in allogeneic hematopoietic cell transplantation

    Pranay Hegde, Lisa Rybicki, Sheila Serafino in Bone Marrow Transplantation (2022)

  11. Chapter

    Psychosocial and Patient Support Services in Comprehensive Cancer Centers

    Patient support and psychosocial services are an important aspect of cancer care. Comprehensive cancer centers need to provide a spectrum of these services to provide high-quality and holistic care to cancer p...

    Rajshekhar Chakraborty, Navneet S. Majhail, Jame Abraham in The Comprehensive Cancer Center (2022)

  12. Chapter

    Transplantation and Cellular Therapy

    Comprehensive cancer services include provision of care to patients with advanced hematologic malignancies, among whom some patients are candidates for hematopoietic cell transplantation (HCT). HCT is a comple...

    Navneet S. Majhail, Marcos De Lima in The Comprehensive Cancer Center (2022)

  13. Article

    The Democratization of Scientific Conferences: Twitter in the Era of COVID-19 and Beyond

    The coronavirus disease 2019 (COVID-19) pandemic has had profound impacts upon scientific discourse in our field, most prominently through the abrupt transition of malignant hematology conferences to all-digit...

    Rahul Banerjee, Amar H. Kelkar, Aaron C. Logan in Current Hematologic Malignancy Reports (2021)

  14. No Access

    Reference Work Entry In depth

    Allogeneic Transplant Overview and Matched Related Donor Transplant

    Allogeneic hematopoietic cell transplantation utilizes the potential of an alloreactive graft-versus-tumor effect for the treatment of hematologic malignancies and other malignant and nonmalignant diseases. Si...

    Navneet S. Majhail in Contemporary Bone Marrow Transplantation (2021)

  15. No Access

    Article

    To D or not to D: vitamin D in hematopoietic cell transplantation

    Vitamin D plays an essential role in bone health, immune tolerance, and immune modulation. Autologous and allogeneic hematopoietic cell transplantation (HCT) recipients are at increased risk of vitamin D defic...

    Sanghee Hong, Christina S. Ferraro, Betty K. Hamilton in Bone Marrow Transplantation (2020)

  16. No Access

    Article

    Age and gender differences in financial distress among hematopoietic cell transplant survivors

    Cancer has long-term financial consequences. Adolescent and young adult (AYA) and middle-aged cancer survivors may experience more financial toxicity than older adults. This study examined age differences in f...

    Salene M. W. Jones, Jean C. Yi, Heather S. L. Jim in Supportive Care in Cancer (2020)

  17. No Access

    Article

    Patient-reported outcomes in acute graft-versus-host disease: optimizing patient care and clinical trial endpoints

    Patient-reported outcomes (PROs) refer to patient perceived and reported health-related quality of life (HRQOL), functional status, and symptom burden. PROs have become an important measure in oncologic care t...

    Sagar S. Patel, Brittany Lapin, Navneet S. Majhail in Bone Marrow Transplantation (2020)

  18. No Access

    Article

    Engaging hematopoietic cell transplantation patients and caregivers in the design of print and mobile application individualized survivorship care plan tools

    INSPIRE (INteractive Survivorship Program with Information and REsources) is an online health program that includes a mobile app, website, health action plan, and individualized survivorship care plans for adu...

    Jaime M. Preussler, Ellen M. Denzen, Navneet S. Majhail in Supportive Care in Cancer (2020)

  19. No Access

    Article

    Healthcare Costs of Treating Privately Insured Patients with Acute Myeloid Leukemia in the United States from 2004 to 2014: A Generalized Additive Modeling Approach

    The primary objective of this study was to predict healthcare cost trajectories for patients with newly diagnosed acute myeloid leukemia (AML) receiving allogeneic hematopoietic cell transplantation (alloHCT),...

    Lih-Wen Mau, Jaime M. Preussler, Linda J. Burns, Susan Leppke in PharmacoEconomics (2020)

  20. No Access

    Article

    Transplant center characteristics and survival after allogeneic hematopoietic cell transplantation in adults

    Allogeneic hematopoietic cell transplantation (alloHCT) is a highly specialized procedure. We surveyed adult transplant centers in the United States (US) and then used data reported to the Center for Internati...

    Navneet S. Majhail, Lih-Wen Mau, Pintip Chitphakdithai in Bone Marrow Transplantation (2020)

previous disabled Page of 2